GME : Fellowship : Oncology-Hematology

• Program Director's Message
• At-A-Glance
• Curriculum
• Rotations in Months
• Key Faculty

Harry Staszewski, MD Program Director's Message Our focus is to develop clinicians who are adept at prevention, screening, diagnosis and treatment of a broad range of malignancies, as well as benign hematologic disease. This is a three-year program of comprehensive clinical training in both medical oncology and hematology, satisfying double-board eligibility, with protected time to pursue an original research project. Fellows are trained in all procedures relating to oncology/hematology, including bone marrow aspiration, biopsy and interpretation, coagulation testing, blood banking, chemotherapy administration and stem cell transplantation. The Division is a member of the Southwest Oncology Group and is a site for numerous investigational drug and treatment trials in hematologic, as well as malignant disease.

TOP

• Over the past five years, all fellowship graduates have obtained board certification in hematology and medical oncology
• Access to a wide variety of pathology, including more than 1,600 new cancer diagnoses annually
• Outpatient continuity experience maintained throughout the three years
• Extensive didactic training includes eight weekly hematology and oncology conferences
• Full range of clinical programs, including autologous stem cell transplantation program, CALGB clinical trials participation, a dedicated inpatient oncology unit and an outpatient chemotherapy/transfusion treatment suite.
• Generous house staff benefits, including heavily subsidized housing and three complimentary meals per day

TOP

During the first two years, the program is designed to emphasize clinical training in oncology and hematology in six-month alternating blocks. Teaching conferences in both specialties are provided throughout the three years of fellowship training. Fellows make daily consultations on inpatient medical and surgical services, and have a major responsibility for the weekly outpatient Oncology/Hematology Teaching Practice. During the second year, fellows assume a leadership role in teaching and rounding on the inpatient services with house staff and first year fellows. During the third year, there is sustained scholarly activity, as well as continued outpatient experiences. Third-year fellows explore special interests via electives in Gyn or pediatric oncology, tumor pathology, cytogenetics, molecular methods and bone marrow transplantation.

TOP

TOP

• Harry Staszewski, MD, Chief, Oncology and Hematology. Associate Professor of Medicine, SUNY at Stony Brook School of Medicine. Research interests: Coagulation, Acute Leukemia.
• Alexander A. Hindenburg, MD, Attending. Assistant Professor of Medicine, SUNY at Stony Brook School of Medicine. Research interests: Chemotherapy Pharmacology and Drug Resistance, Myelodysplasia
• Jeffrey Schneider, MD, Attending.  Assistant Professor of Medicine, SUNY at Stony Brook School of Medicine. Research interests: Breast and Gynecologic Oncology, High Dose Chemotherapy and Autologous Transplantation
• Michael E. Garrison, MD, Attending. Assistant Professor of Medicine, SUNY at Stony Brook School of Medicine. Research interests: Melanoma, Acute Leukemia.
• Nina D’Abreo, MD, Attending.  Assistant Professor of Medicine, SUNY at Stony Brook School of Medicine.  Research interests: Breast Cancer, Hematologic disorders.

For further information, contact:

Harry Staszewski, MD
Chief, Division of Oncology and Hematology
Winthrop-University Hospital
200 Old Country Road, Suite 450
Mineola, NY 11501

Tel: (516) 663-4608
Fax: (516) 663-4613
E-mail: afischer@winthrop.org